Entering text into the input field will update the search result below

Sanofi's Soliqua 100/33 now available in U.S

  • Zealand Pharma (OTCPK:ZLDPF) reports that Sanofi (SNY)  announces that FDA approved Soliqua(TM) 100/33 (insulin glargine 100 Units/mL & lixisenatide 33 mcg/mL injection) and Adlyxin (lixisenatide) is now available by prescription in U.S. pharmacies. Soliqua 100/33 is indicated for the treatment of adults with type 2 diabetes inadequately controlled on basal insulin (less than 60 Units daily) or lixisenatide.
  • Sanofi is offering Soliqua 100/33 at a $0 co-pay** for eligible U.S. patients with commercial insurance and is working to secure coverage for Soliqua 100/33 on health plans nationwide.
  • Under the terms of the license agreement between Sanofi and Zealand, Sanofi is responsible for all development and commercialization. Last month, Zealand received the $25M milestone payment triggered by the FDA approval of Soliqua 100/33. Zealand is eligible to receive remaining milestone payments of up to $110M as well as royalties on global sales.

Recommended For You

About ZLDPF Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ZLDPF--
Zealand Pharma A/S